These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 19858253

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K, Chung EK, Knoderer CA, Buenger LE, Healy DP, Dees J, Crumby AS, Kays MB.
    Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ, Shankar V, Schlichting C, Kuti JL.
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP.
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [Abstract] [Full Text] [Related]

  • 8. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S, Pai MP, Lodise TP.
    J Antimicrob Chemother; 2017 Oct 01; 72(10):2813-2816. PubMed ID: 29091209
    [Abstract] [Full Text] [Related]

  • 9. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
    Chen R, Qian Q, Sun MR, Qian CY, Zou SL, Wang ML, Wang LY.
    Eur J Drug Metab Pharmacokinet; 2016 Aug 01; 41(4):363-72. PubMed ID: 25894901
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
    Kuti JL, Nightingale CH, Quintiliani R, Nicolau D.
    Diagn Microbiol Infect Dis; 2002 Sep 01; 44(1):51-7. PubMed ID: 12376031
    [Abstract] [Full Text] [Related]

  • 11. Dose-Exposure Simulation for Piperacillin-Tazobactam Dosing Strategies in Infants and Young Children.
    Thibault C, Kassir N, Théorêt Y, Varin F, Litalien C, Autmizguine J.
    J Popul Ther Clin Pharmacol; 2017 Aug 21; 24(3):e33-344. PubMed ID: 28873292
    [Abstract] [Full Text] [Related]

  • 12. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
    Sime FB, Hahn U, Warner MS, Tiong IS, Roberts MS, Lipman J, Peake SL, Roberts JA.
    Antimicrob Agents Chemother; 2017 Nov 21; 61(11):. PubMed ID: 28807922
    [Abstract] [Full Text] [Related]

  • 13. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
    Chen Y, Lu J, Dong M, Wu D, Zhu Y, Li Q, Chen C, Li Z.
    Eur J Clin Pharmacol; 2016 Dec 21; 72(12):1479-1488. PubMed ID: 27644691
    [Abstract] [Full Text] [Related]

  • 14. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Guet-Revillet H, Tomini E, Emirian A, Join-Lambert O, Lécuyer H, Zahar JR, Jullien V.
    Int J Antimicrob Agents; 2017 Jan 21; 49(1):62-66. PubMed ID: 27876276
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
    Kim MK, Capitano B, Mattoes HM, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP.
    Pharmacotherapy; 2002 May 21; 22(5):569-77. PubMed ID: 12013355
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
    Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB.
    J Clin Pharmacol; 2015 Aug 21; 55(8):899-908. PubMed ID: 25823963
    [Abstract] [Full Text] [Related]

  • 17. Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales.
    Cojutti PG, Pai MP, Tonetti T, Siniscalchi A, Viale P, Pea F.
    Antimicrob Agents Chemother; 2024 Apr 03; 68(4):e0140423. PubMed ID: 38411995
    [Abstract] [Full Text] [Related]

  • 18. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A, Sutherland CA, Kuti JL, Nicolau DP.
    Pharmacotherapy; 2007 Nov 03; 27(11):1490-7. PubMed ID: 17963458
    [Abstract] [Full Text] [Related]

  • 19. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
    Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, Depuydt P, Decruyenaere J, Lipman J, Wallis SC, De Waele JJ.
    Crit Care; 2013 May 03; 17(3):R84. PubMed ID: 23642005
    [Abstract] [Full Text] [Related]

  • 20. Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.
    Gill CM, Nicolau DP, ERACE-PA Global Study Group.
    Clin Ther; 2023 Jan 03; 45(1):72-77. PubMed ID: 36593150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.